Cardiogenic shock was defined as a systolic blood pressure of less than 80 mm Hg in the absence of hypovolemia and associated with cyanosis, cold extremities, changes in mental status, persistent oliguria, or congestive heart failure (6 (link),7 (link)). The definition of cardiogenic shock remained the same during all periods studied. This disorder was defined so that patients with classic signs and symptoms of this clinical syndrome would be included.
>
Disorders
>
Sign or Symptom
>
Cyanosis
Cyanosis
Cyanosis is a bluish discoloration of the skin and mucous membranes caused by an abnormal amount of deoxygenated hemoglobin in the blood.
It can indicate a serious underlying condition, such as heart or lung disease, and requires prompt medical attention.
PubCompare.ai's AI-powered tools can help researchers optimize their cyanosis studies by identifying the best reproducible, accurate protocols from the literature, preprints, and patents.
Leverage the platform's data-driven analysis to locate the optimal products and procedures for your cyanosis research, ensuring reiable, data-driven findings.
It can indicate a serious underlying condition, such as heart or lung disease, and requires prompt medical attention.
PubCompare.ai's AI-powered tools can help researchers optimize their cyanosis studies by identifying the best reproducible, accurate protocols from the literature, preprints, and patents.
Leverage the platform's data-driven analysis to locate the optimal products and procedures for your cyanosis research, ensuring reiable, data-driven findings.
Most cited protocols related to «Cyanosis»
Angina, Unstable
Closure, Hospital
Common Cold
Congestive Heart Failure
Cyanosis
Diagnosis
Inpatient
Long-Term Care
Oliguria
Patient Discharge
Patients
Respiratory Diaphragm
Shock, Cardiogenic
Syndrome
Systolic Pressure
Anesthetics
BLOOD
Coarctation, Aortic
Cyanosis
Ethics Committees, Research
Fentanyl
Homeostasis
Isoflurane
Midazolam
Oximetry
Oxygen Saturation
Pancuronium
Patients
Pressure
Spectroscopy, Near-Infrared
Surgical Procedure, Cardiac
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Age Groups
Bronchodilator Agents
Child
Cough
Cyanosis
Dentatorubral-Pallidoluysian Atrophy
Ethics Committees, Research
Haemophilus influenzae type b polysaccharide vaccine
Legal Guardians
Lethargy
Parent
Perch
Pneumococcal Vaccine
Pneumonia
Respiratory Rate
Seizures
Signs and Symptoms, Respiratory
Specimen Collection
Vaccination
Virus Vaccine, Influenza
Wall, Chest
Wheezing
During an illness visit, pneumonia was diagnosed using WHO criteria and its severity graded [18] . Children with cough or difficulty breathing and a fast respiratory rate, as determined by age specific cut offs (<2 months ≥60 breaths per minute; 2 months –1 year ≥50 breaths per minute and >1 year ≥40 breaths per minute), but no severe signs were diagnosed as having pneumonia. Severe pneumonia was diagnosed in children with cough or difficulty breathing and chest indrawing. Children fulfilling the severe pneumonia criteria but who also had cyanosis or inability to suck were diagnosed with very severe pneumonia.
Pulse oximetry (Hand –held pulse oximeter 512, Respironics), a complete blood count (CBC) (PocH-one 100i, Sysmex), C-reactive protein (CRP) (NycoCard, Axis-Shield), nasopharyngeal aspirate (NPA), and a chest radiograph (CXR) were done on all children with diagnosed pneumonia. NPAs were tested for influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and adenovirus by rRT-PCR [19] .
CXRs were interpreted by two clinicians using the WHO criteria [10] . Results were compared and any conflicting CXRs were examined by a third clinician and the majority diagnosis was used. Where there was no agreement the CXR was deemed uninterpretable.
Pneumonia treatment followed the recommendations in the WHO pocket book of hospital care for children [18] .
Pulse oximetry (Hand –held pulse oximeter 512, Respironics), a complete blood count (CBC) (PocH-one 100i, Sysmex), C-reactive protein (CRP) (NycoCard, Axis-Shield), nasopharyngeal aspirate (NPA), and a chest radiograph (CXR) were done on all children with diagnosed pneumonia. NPAs were tested for influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and adenovirus by rRT-PCR [19] .
CXRs were interpreted by two clinicians using the WHO criteria [10] . Results were compared and any conflicting CXRs were examined by a third clinician and the majority diagnosis was used. Where there was no agreement the CXR was deemed uninterpretable.
Pneumonia treatment followed the recommendations in the WHO pocket book of hospital care for children [18] .
Adenoviruses
ARID1A protein, human
Chest
Child
Cough
C Reactive Protein
Cyanosis
Diagnosis
Epistropheus
Human Metapneumovirus
Human respiratory syncytial virus
Nasopharynx
Orthomyxoviridae
Oximetry, Pulse
Pneumonia
Pulse Rate
Radiography, Thoracic
Respiratory Rate
Central Nervous System
Child
Childbirth
Chromosomes
Congenital Abnormality
Cyanosis
Ethics Committees, Research
Gestational Age
Heart Diseases
High-Risk Pregnancy
Hospitalization
Infant
Infant, Newborn
Legal Guardians
Mechanical Ventilation
Oxygen
Parent
Preterm Infant
Reliance resin cement
Most recents protocols related to «Cyanosis»
A hospital-based epidemiological survey was conducted in Guangxi, a province in southern China where HFMD is prevalent. Cases of severe HFMD from 2014 to 2018 were collected from Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control (CDC) system. The definition of severe HFMD was referred to the “diagnosis and treatment guidelines for HFMD” (2010)” [11 ], and the diagnosis criteria are as follow: (1) frequent convulsions, coma and cerebral hernia; (2) breathing difficulties, cyanosis, bloody frothy sputum and pulmonary rales; and (3) shock and circulatory insufficiency. In our study, subjects were included if: (1) Severe HFMD cases: clinical severity was defined as the patient experienced any neurological complications (aseptic meningitis, encephalitis, encephalomyelitis, acute flaccid paralysis, or autonomic nervous system dysregulation) and/or cardiopulmonary complications (pulmonary edema, pulmonary hemorrhage, or cardiorespiratory failure) and/or circulatory system symptoms (pale face, cold limbs, fingers (toes) cyanosis, cold sweat, et al.), Severe HFMD cases were classified if the patients experienced any symptoms belonging to the clinical severity, others were categorized as mild cases [11 , 12 (link)]. (2) Patient’s parents approved of participation; (3) Individuals with completed investigation data. Subjects were excluded if: (1) The neurological dysfunction was caused by non-HFMD; (2) Patients with incomplete investigation data. All participants understood the purpose of the study and signed the informed consent forms. An investigation was performed following the relevant guidelines and regulations; cases of severe HFMD from 2014 to 2018 were collected from Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control (CDC) system, the investigation was done by the staff of the CDC.
The sample size can be calculated by the following formula: . The annual proportion of severe HFMD diseases was set at about 20% [3 (link), 10 (link)], then we calculated the sample size using the PASS software.
The sample size can be calculated by the following formula: . The annual proportion of severe HFMD diseases was set at about 20% [3 (link), 10 (link)], then we calculated the sample size using the PASS software.
acute flaccid paralysis
Aseptic Meningitis
Cardiovascular System
Comatose
Common Cold
Cyanosis
Diagnosis
Dysautonomia
Dyspnea
Encephalitis
Encephalocele
Encephalomyelitis
Face
Fingers
Hemoptysis
Hemorrhage
Lung
Parent
Patients
Pulmonary Edema
Seizures
Shock
Sweat
Systems, Nervous
Toes
This retrospective study was approved by the ethical review board of our hospital (IRB number: JD-HG-2021-32). Informed consent was obtained from all patients. Fifty-seven patients with acute arterial embolism in our hospital were enrolled in the study between January 2015 and December 2017, including 45 male and 12 female adults aged from 40 to 88 years, with an average age of 73.52 years. In total, 95 ROIs were detected in these patients, including old emboli (50) and new thromboses (45).
The inclusion criteria were: The exclusion criteria included: Figure 2 shows the details of patient selection.
a) Clinical manifestations of acute onset, manifested by varying degrees of sudden limb pain, followed by numbness, paleness, cyanosis, dyskinesia, cold limbs, arterial pulse weakening, or disappearance of symptoms;
b) Gross specimen showing that the thrombosis head was sclerotic and the tail thrombosis was soft; pathological diagnosis showing that the head thromboses was white and the tail thromboses was red;
c) Embolus taken immediately after CTA examination of the lower extremities at DSA.
a) Artifacts in images;
b) Unclear popliteal artery lumen;
c) Images could not be matched;
d) Nephrotic syndrome.
Adult
Arteries
Common Cold
Cyanosis
Diagnosis
Dyskinesias
Embolism
Ethical Review
Head
Lower Extremity
Males
Nephrotic Syndrome
Pains, Acute
Patients
Popliteal Artery
Pulse Rate
Sclerosis
Tail
Thrombosis
Woman
Integrating the above, a list of features was selected for the data collection phase. Considering the results of Round 1 of the Delphi procedure, an approach that compromised between comprehensiveness, veracity, practicality and expected correlation with clinical outcome was chosen. Features of equivalent meaning were combined (accessory muscle use and grunting were combined as respiratory distress for example) or where a quantifiable candidate was available (such as in the case of cyanosis or peripheral oxygen saturation), the quantifiable metric was selected. For level of consciousness, both the AVPU scale (an ordinal score for consciousness—alert, response to verbal stimuli, response to pain, unresponsive) and a broader variable of altered level of consciousness were available (16 (link)). These features represent clinically detectable markers of specific organ dysfunctions. In view of the high prevalence of human immunodeficiency virus (HIV) and malnutrition in South Africa (17 (link)–19 ), the current status of HIV diagnosis and treatment together with anthropometry values were also included for collection as these were thought to be potentially informative features in this clinical setting.
Consciousness
Cyanosis
Diagnosis
HIV
Malnutrition
Muscle Tissue
Pain
Respiratory Rate
Saturation of Peripheral Oxygen
All volunteers completed a test of seven signs and symptoms of CMS based on the “Qinghai CMS Score,” which is based on the following symptoms: breathlessness and/or palpitations, sleep disturbance, cyanosis, dilatation of veins, paresthesia, headache, tinnitus, and a final value of 3 if the Hb value is ≥ 21 g/dL.[20 (link)]
Cyanosis
Dyspnea
Dyssomnias
Headache
Paresthesia
Tinnitus
Varices
Voluntary Workers
The study was conducted in Northern Lesotho from 28.12.2020 to 30.09.2021 at the Government District Hospital of Mokhotlong and the St Charles Missionary Hospital Seboche and additionally from 21.01.2021 to 12.02.2021 at the Butha-Buthe Government District Hospital. These hospitals serve a population of about 220’000, mainly living in rural communities scattered over a mountainous area in Northern Lesotho. During the 10 months of the study implementation, the Ministry of Health of Lesotho reported the surge of three waves of increased incidence of COVID-19 cases and implemented social mobility restrictions and lockdowns of different intensity. Lesotho’s first COVID-19 wave started in December 2020, the second in May 2021 and the third in September 2021 [14 ].
As part of routine procedures, all children ≥ 5 years, adolescents, and adults attending health services at one of the hospitals were pre-screened for COVID-19 related symptoms at the entrance gate. Any person with body temperature ≥38°C (non-contact forehead thermometer) or reporting at least one out of the following 10 symptoms was eligible for SARS-CoV-2 testing: fever/chills, cough, tiredness, dyspnea, sore throat, body pain, diarrhea, loss of taste/smell, recent weight loss, night sweats. Further eligible were individuals reporting close contact to a probable or confirmed COVID-19 case in the last 14 days, defined as contact <1m for ≥15 min, direct physical contact, or direct care without appropriate personal protective equipment.
Informed consent was obtained after pre-screening. A focused medical history was obtained, and a clinical examination was performed on each subject enrolled in the study. Individuals who were deemed critically ill by the healthcare provider, i.e., adults with altered mental status, tachypnea (≥22/min), SpO2<94%, or systolic blood pressure <100mgHg, and children with signs of pneumonia and central cyanosis, SpO2<94%, general danger signs, or tachypnea (5–9 yrs ≥ 30/min, ≥10 yrs ≥ 20/min) were assessed by a hospital physician, who decided whether the participant could remain in the study for all investigations or immediately referred to emergency care.
As part of routine procedures, all children ≥ 5 years, adolescents, and adults attending health services at one of the hospitals were pre-screened for COVID-19 related symptoms at the entrance gate. Any person with body temperature ≥38°C (non-contact forehead thermometer) or reporting at least one out of the following 10 symptoms was eligible for SARS-CoV-2 testing: fever/chills, cough, tiredness, dyspnea, sore throat, body pain, diarrhea, loss of taste/smell, recent weight loss, night sweats. Further eligible were individuals reporting close contact to a probable or confirmed COVID-19 case in the last 14 days, defined as contact <1m for ≥15 min, direct physical contact, or direct care without appropriate personal protective equipment.
Informed consent was obtained after pre-screening. A focused medical history was obtained, and a clinical examination was performed on each subject enrolled in the study. Individuals who were deemed critically ill by the healthcare provider, i.e., adults with altered mental status, tachypnea (≥22/min), SpO2<94%, or systolic blood pressure <100mgHg, and children with signs of pneumonia and central cyanosis, SpO2<94%, general danger signs, or tachypnea (5–9 yrs ≥ 30/min, ≥10 yrs ≥ 20/min) were assessed by a hospital physician, who decided whether the participant could remain in the study for all investigations or immediately referred to emergency care.
Adolescent
Ageusia
Body Temperature
Child
Chills
Cough
COVID 19
Critical Illness
Cyanosis
Diarrhea
Dyspnea
Fatigue
Fever
Forehead
Health Personnel
Human Body
Missionaries
Pain
Physical Examination
Physicians
Pneumonia
Respiratory Diaphragm
Rural Communities
SARS-CoV-2
Saturation of Peripheral Oxygen
Sense of Smell
Service, Emergency Medical
Social Mobility
Sore Throat
Sweat
Systolic Pressure
Taste
Thermometers
Top products related to «Cyanosis»
Sourced in United States, Germany, Japan, Italy, Canada, United Kingdom, Sweden, Sao Tome and Principe, Macao, China
Avertin is a laboratory reagent used as an anesthetic agent in various animal studies and experiments. It is a combination of 2,2,2-tribromoethanol and tert-amyl alcohol. Avertin induces a state of general anesthesia in animals, allowing for safe and controlled procedures to be performed.
Sourced in United States
The VentElite 55-7040 is a ventilator system designed for laboratory research. It provides controlled ventilation to small animals during experiments. The device features adjustable tidal volume, breathing rate, and inspiratory/expiratory ratio to accommodate various research requirements.
Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, Japan, Italy, Canada, Hungary, Macao
Pentobarbital sodium is a laboratory chemical compound. It is a barbiturate drug that acts as a central nervous system depressant. Pentobarbital sodium is commonly used in research and scientific applications.
Sourced in Italy
The Pony FX is a compact, high-performance laboratory centrifuge designed for a variety of applications. It features a brushless motor and can achieve speeds of up to 6,000 RPM, making it suitable for a range of sample separation tasks. The Pony FX is a versatile and reliable piece of equipment for use in clinical, research, and educational settings.
Sourced in United States
The Model 683 is a syringe pump that is designed for precise fluid delivery in laboratory applications. It features a microprocessor-controlled stepper motor drive and can accommodate a wide range of syringe sizes. The pump can deliver flow rates from 0.001 μL/hr to 220.8 mL/min, with an accuracy of ±0.5%.
Sourced in Italy
The Quark C12x is a calorimetry device designed for indirect calorimetry measurements. It utilizes gas analysis to determine the respiratory exchange ratio and energy expenditure.
Sourced in United States
The Nellcor™ Bedside SpO2 Patient Monitoring System is a device designed to measure and monitor a patient's oxygen saturation levels in the blood. It utilizes pulse oximetry technology to provide continuous, noninvasive monitoring of the patient's oxygen saturation.
Sourced in Japan
The UA-767 Plus is a compact, digital blood pressure monitor designed for clinical use. It features an oscillometric measurement method and is capable of measuring blood pressure and pulse rate. The device is powered by batteries and includes a LCD display to show the measured values.
Sourced in Germany, United Kingdom
Fentanyl is a synthetic opioid analgesic used in laboratory settings for research purposes. It is a powerful pain-relieving substance that is typically used in controlled medical environments. The core function of Fentanyl is to serve as a research tool for scientific investigations, but its detailed applications should be discussed with qualified professionals.
More about "Cyanosis"
Cyanosis is a condition characterized by a bluish discoloration of the skin and mucous membranes, caused by an abnormal amount of deoxygenated hemoglobin in the blood.
This can be an indicator of a serious underlying medical issue, such as heart or lung disease, and requires prompt medical attention.
Researchers studying cyanosis can leverage PubCompare.ai's AI-powered tools to optimize their research protocols.
The platform's data-driven analysis can help identify the best reproducible and accurate protocols from the literature, preprints, and patents.
This can ensure reliable and data-driven findings.
Some key subtopics and related terms to consider in cyanosis research include: Deoxygenated hemoglobin, Anoxia, Hypoxia, Dyspnea, Respiratory distress, Cardiovascular disease, Pulmonary disease, Avertin (a barbiturate anesthetic), VentElite 55-7040 (a ventilator), Pentobarbital sodium (a sedative), Pony FX (a vital signs monitor), Model 683 (a pulse oximeter), Quark C12x (a cardiac output monitor), NellcorTM Bedside SpO2 Patient Monitoring System (a pulse oximeter), UA‐767 Plus (a blood pressure monitor), and Fentanyl (a potent opioid analgesic).
Leveraging these tools and technologies can enhance the quality and reliability of cyanosis research.
This can be an indicator of a serious underlying medical issue, such as heart or lung disease, and requires prompt medical attention.
Researchers studying cyanosis can leverage PubCompare.ai's AI-powered tools to optimize their research protocols.
The platform's data-driven analysis can help identify the best reproducible and accurate protocols from the literature, preprints, and patents.
This can ensure reliable and data-driven findings.
Some key subtopics and related terms to consider in cyanosis research include: Deoxygenated hemoglobin, Anoxia, Hypoxia, Dyspnea, Respiratory distress, Cardiovascular disease, Pulmonary disease, Avertin (a barbiturate anesthetic), VentElite 55-7040 (a ventilator), Pentobarbital sodium (a sedative), Pony FX (a vital signs monitor), Model 683 (a pulse oximeter), Quark C12x (a cardiac output monitor), NellcorTM Bedside SpO2 Patient Monitoring System (a pulse oximeter), UA‐767 Plus (a blood pressure monitor), and Fentanyl (a potent opioid analgesic).
Leveraging these tools and technologies can enhance the quality and reliability of cyanosis research.